MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
64.62
-2.05
-3.07%
After Hours: 64.58 -0.04 -0.06% 18:56 03/27 EDT
OPEN
67.13
PREV CLOSE
66.67
HIGH
67.63
LOW
64.15
VOLUME
889.25K
TURNOVER
--
52 WEEK HIGH
69.35
52 WEEK LOW
14.80
MARKET CAP
5.46B
P/E (TTM)
-31.0285
1D
5D
1M
3M
1Y
5Y
1D
LifeSci Capital Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
TipRanks · 8h ago
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON)
TipRanks · 1d ago
CG ONCOLOGY INC <CGON.O>: UBS RAISES TARGET PRICE TO $90 FROM $60
Reuters · 2d ago
CG Oncology price target raised to $90 from $60 at UBS
TipRanks · 2d ago
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
Reuters · 2d ago
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
TipRanks · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), ARS Pharmaceuticals (SPRY) and CG Oncology, Inc. (CGON)
TipRanks · 5d ago
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.